——The first global innovative biologic in development for the treatment of dry eye disease in China

——The approval for the clinical trial will advance the development of innovative product pipeline at Harbour BioMed

The National Medical Products Administration (NMPA) has recently granted Harbour BioMed to start phase II clinical trial with HBM9036, a global innovative biologic being developed for the treatment of  dry eye disease. Dr. Xiaoxiang Chen, Executive Vice President and Head of Clinical Development and Regulatory Science at Harbour BioMed, commented: “We are very pleased to receive the approval to start the clinical trials in China. The development of HBM9036 ophthalmic solution will address the tremendous unmet medical needs in treating the dry eye disease in China.”   

HBM9036 ophthalmic solution is a molecularly engineered tumor necrosis factor (TNF) receptor 1 (TNFR1) fragment. It is a polypeptide drug with molecule fragmentation and engineering techniques applied for enhanced tissue distribution, increased stability, and high potency of neutralizing local TNF. It has the indication potential in treating inflammatory eye diseases including dry eye, uveitis, and wet macular degeneration.

Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed, commented: “Harbour BioMed aims at addressing the unmet medical needs of patients in China and beyond.. We plan to work with top tier experts and the most advanced technology in the field to bring innovative solutions to patients in need. “ 

About Harbour BioMed

 
Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on oncology and immunology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners and select acquisitions.

 
The Company’s proprietary antibody technology platforms Harbour Mice^® generate fully human monoclonal antibodies in two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE^®) are capable of delivering tumor killing effects unachievable by traditional combination therapies. Integrating Harbour Mice^® with single B cell cloning platform, our antibody discovery engine is highly unique and efficient for development of next generation therapeutic antibodies. 

For further information, please refer to www.harbourbiomed.com

Contact：

Yue Wang

Rm 311, 866 Halei Road, Pudong District, Shanghai

yue.wang@harbourbiomed.com